K
Klaus Pantel
Researcher at University of Hamburg
Publications - 566
Citations - 36666
Klaus Pantel is an academic researcher from University of Hamburg. The author has contributed to research in topics: Circulating tumor cell & Cancer. The author has an hindex of 90, co-authored 486 publications receiving 29848 citations.
Papers
More filters
Journal ArticleDOI
Expression of Extracellular Matrix Metalloproteases Inducer on Micrometastatic and Primary Mammary Carcinoma Cells
Natalie Reimers,Kristine Zafrakas,Volker Assmann,Cornelia Egen,Lutz Riethdorf,Sabine Riethdorf,Jürgen Berger,Sebastian Ebel,Fritz Jänicke,Guido Sauter,Klaus Pantel +10 more
TL;DR: EMMPRin expression in primary tumor predicts an unfavorable prognosis in breast cancer, suggesting a crucial role of EMMPRIN in progression of human mammary carcinomas.
Journal ArticleDOI
Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients
TL;DR: In this article, the diagnostic potential of circulating cell-free microRNAs targeting PTEN in breast cancer was examined on pre-operative serum samples of 102 patients with early breast cancer and a subset of 34 post-operative samples, as well as of 32 patients with benign breast disease and 53 healthy women.
Journal ArticleDOI
A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells
G E Hvichia,Z Parveen,C. Wagner,Melanie Janning,Julia Quidde,Alexander Stein,Volkmar Müller,Sonja Loges,R P L Neves,Nikolas H. Stoecklein,Harriet Wikman,Sabine Riethdorf,Klaus Pantel,Tobias M. Gorges +13 more
TL;DR: The epitope independent Parsortix™ system enables the isolation of viable CTCs at a very high purity and will help to broaden research into the mechanisms of cancer as well as facilitating the use of C TCs as “liquid biopsies.”
Journal Article
MAGE-A Gene Expression Pattern in Primary Breast Cancer
Marcus Otte,Menelaos Zafrakas,Lutz Riethdorf,Uwe Pichlmeier,Thomas Löning,Fritz Jänicke,Klaus Pantel +6 more
TL;DR: A preferential expression of MAGE-A is observed in patients at a higher risk of recurrence: those harboring tumors with high levels of the protease urokinase-type plasminogen activator and its inhibitors, high score of the Ki-67 proliferation antigen, and lesser degree of differentiation.
Journal Article
Detection and Clinical Implications of Early Systemic Tumor Cell Dissemination in Breast Cancer
TL;DR: The existing tumor cell assays are reviewed and their current clinical relevance and perspectives for the clinical management of breast cancer patients are discussed.